Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Return on Sales
Return on Investment
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
Profitability performance between 2016 and 2021 was characterized by a period of significant volatility, specifically centered around 2018, followed by a robust recovery by the end of the period. While gross margins remained relatively resilient, bottom-line profitability and efficiency ratios experienced sharp contractions before returning to or exceeding baseline levels.
- Margin Analysis
- Gross profit margin exhibited moderate fluctuations, peaking at 49.14% in 2017 and reaching a low of 44.27% in 2020. Despite these swings, the margin remained within a range of approximately five percentage points, suggesting a stable core cost structure. In contrast, the operating profit margin showed more pronounced volatility, dipping to 8.67% in 2020 before climbing to a period high of 13.82% in 2021. Net profit margin experienced the most severe decline, dropping from 9.10% in 2017 to 1.95% in 2018, which indicates the occurrence of significant non-operating expenses or one-time charges during that fiscal year. By 2021, the net profit margin recovered to 10.33%.
- Return on Investment Metrics
- Return on Equity (ROE) and Return on Assets (ROA) mirrored the trajectory of net profit margins. ROE declined sharply from 12.79% in 2016 to a trough of 1.48% in 2018, before recovering to 8.84% by 2021. Similarly, ROA fell to 0.58% in 2018 from a 2016 level of 3.81%, eventually returning to 3.88% in 2021. This pattern suggests that the decline in overall profitability in 2018 severely impaired capital efficiency, although subsequent years demonstrate a return to normalized asset and equity utilization.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Gross Profit Margin
| Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||
| Gross profit | 9,427) | 7,577) | 8,288) | 7,262) | 5,942) | 5,991) | |
| Revenues | 20,248) | 17,117) | 17,290) | 15,983) | 12,093) | 12,483) | |
| Profitability Ratio | |||||||
| Gross profit margin1 | 46.56% | 44.27% | 47.94% | 45.44% | 49.14% | 47.99% | |
| Benchmarks | |||||||
| Gross Profit Margin, Competitors2 | |||||||
| Abbott Laboratories | 52.21% | — | — | — | — | — | |
| Elevance Health Inc. | 17.09% | — | — | — | — | — | |
| Intuitive Surgical Inc. | 69.32% | — | — | — | — | — | |
| Medtronic PLC | 65.19% | — | — | — | — | — | |
| UnitedHealth Group Inc. | 23.60% | — | — | — | — | — | |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
1 2021 Calculation
Gross profit margin = 100 × Gross profit ÷ Revenues
= 100 × 9,427 ÷ 20,248 = 46.56%
2 Click competitor name to see calculations.
Between 2016 and 2021, total revenues exhibited a strong overall growth trajectory, increasing from 12,483 million USD to 20,248 million USD. Gross profit followed a similar upward trend, rising from 5,991 million USD to 9,427 million USD over the same period. Despite the consistent growth in absolute dollar values, the efficiency of production and cost management demonstrated significant variability.
- Gross Profit Margin Volatility
- The gross profit margin did not follow a linear path, fluctuating between a peak of 49.14% in 2017 and a trough of 44.27% in 2020. Notable contractions occurred in 2018 and 2020, indicating periods where the cost of goods sold increased at a disproportionate rate relative to revenue growth.
- Correlation Between Revenue Growth and Profitability
- Analysis indicates that substantial increases in revenue did not consistently translate into margin expansion. For instance, the significant revenue increase observed between 2017 and 2018 was accompanied by a margin decline from 49.14% to 45.44%, suggesting that the expansion during this phase may have been driven by lower-margin product lines or increased operational expenditures.
- Recent Recovery Trends
- Following the low point in 2020, a recovery in profitability was observed in 2021, with the gross profit margin rising to 46.56%. This recovery aligned with the highest recorded revenue in the period, suggesting an improvement in operational leverage or a more favorable product mix toward the end of the analyzed timeframe.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Operating Profit Margin
| Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||
| Operating income | 2,799) | 1,484) | 1,760) | 1,497) | 1,478) | 1,430) | |
| Revenues | 20,248) | 17,117) | 17,290) | 15,983) | 12,093) | 12,483) | |
| Profitability Ratio | |||||||
| Operating profit margin1 | 13.82% | 8.67% | 10.18% | 9.37% | 12.22% | 11.46% | |
| Benchmarks | |||||||
| Operating Profit Margin, Competitors2 | |||||||
| Abbott Laboratories | 19.56% | — | — | — | — | — | |
| Elevance Health Inc. | 5.15% | — | — | — | — | — | |
| Intuitive Surgical Inc. | 31.89% | — | — | — | — | — | |
| Medtronic PLC | 14.89% | — | — | — | — | — | |
| UnitedHealth Group Inc. | 8.40% | — | — | — | — | — | |
| Operating Profit Margin, Sector | |||||||
| Health Care Equipment & Services | 9.13% | — | — | — | — | — | |
| Operating Profit Margin, Industry | |||||||
| Health Care | 18.04% | — | — | — | — | — | |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
1 2021 Calculation
Operating profit margin = 100 × Operating income ÷ Revenues
= 100 × 2,799 ÷ 20,248 = 13.82%
2 Click competitor name to see calculations.
The financial performance from 2016 to 2021 is characterized by consistent top-line expansion contrasted with fluctuating operational efficiency. While revenues trended upward over the six-year period, the operating profit margin experienced several cycles of contraction and expansion, culminating in a significant peak in the final year.
- Revenue Growth Trends
- A sustained increase in revenues is observed, rising from US$ 12,483 million in 2016 to US$ 20,248 million in 2021. A particularly sharp increase occurred between 2017 and 2018, where revenues grew by approximately 32%, shifting the company to a higher revenue scale that was maintained through the end of the period.
- Operating Income Volatility
- Operating income exhibited inconsistent growth patterns. After a period of stability between 2016 and 2018, a peak was reached in 2019 at US$ 1,760 million. This was followed by a contraction in 2020, with income falling to US$ 1,484 million. A substantial recovery occurred in 2021, with operating income increasing by approximately 88% to reach US$ 2,799 million.
- Operating Profit Margin Analysis
- The operating profit margin fluctuated between a high of 13.82% and a low of 8.67%. A downward trend is evident between 2017 and 2020, where the margin fell from 12.22% to 8.67%, suggesting that operating expenses grew at a rate exceeding revenue growth during this window. This trend reversed sharply in 2021, with the margin expanding to its period high of 13.82%, indicating a significant improvement in operational leverage and cost efficiency.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Net Profit Margin
| Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||
| Net income | 2,092) | 874) | 1,233) | 311) | 1,100) | 976) | |
| Revenues | 20,248) | 17,117) | 17,290) | 15,983) | 12,093) | 12,483) | |
| Profitability Ratio | |||||||
| Net profit margin1 | 10.33% | 5.11% | 7.13% | 1.95% | 9.10% | 7.82% | |
| Benchmarks | |||||||
| Net Profit Margin, Competitors2 | |||||||
| Abbott Laboratories | 16.42% | — | — | — | — | — | |
| Elevance Health Inc. | 4.46% | — | — | — | — | — | |
| Intuitive Surgical Inc. | 29.85% | — | — | — | — | — | |
| Medtronic PLC | 11.97% | — | — | — | — | — | |
| UnitedHealth Group Inc. | 6.06% | — | — | — | — | — | |
| Net Profit Margin, Sector | |||||||
| Health Care Equipment & Services | 7.14% | — | — | — | — | — | |
| Net Profit Margin, Industry | |||||||
| Health Care | 15.24% | — | — | — | — | — | |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
1 2021 Calculation
Net profit margin = 100 × Net income ÷ Revenues
= 100 × 2,092 ÷ 20,248 = 10.33%
2 Click competitor name to see calculations.
The profitability performance from 2016 to 2021 is characterized by significant volatility in net income despite a consistent long-term expansion in total revenues. While revenues grew from US$ 12,483 million in 2016 to US$ 20,248 million in 2021, the net profit margin exhibited sharp fluctuations, reflecting varying operational efficiencies and potential non-recurring financial impacts.
- Margin Volatility and Anomalies
- A critical contraction in profitability occurred in 2018, where the net profit margin dropped to 1.95%, the lowest point in the analyzed period. This decline is particularly notable as it occurred during a period of substantial revenue growth, which increased to US$ 15,983 million, suggesting that significant expenses or one-time charges heavily offset revenue gains during that fiscal year.
- Recovery and Stabilization Trends
- Following the 2018 low, the margin recovered to 7.13% in 2019 as net income rebounded to US$ 1,233 million. A subsequent moderate decline to 5.11% was observed in 2020, coinciding with a slight contraction in total revenues to US$ 17,117 million.
- Peak Profitability Analysis
- The period concluded with a significant surge in 2021, with the net profit margin reaching a six-year high of 10.33%. This peak was driven by net income increasing to US$ 2,092 million, representing a substantial improvement in the conversion of revenue into profit as total revenues surpassed the US$ 20 billion threshold.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Return on Equity (ROE)
| Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||
| Net income | 2,092) | 874) | 1,233) | 311) | 1,100) | 976) | |
| Shareholders’ equity | 23,677) | 23,765) | 21,081) | 20,994) | 12,948) | 7,633) | |
| Profitability Ratio | |||||||
| ROE1 | 8.84% | 3.68% | 5.85% | 1.48% | 8.50% | 12.79% | |
| Benchmarks | |||||||
| ROE, Competitors2 | |||||||
| Abbott Laboratories | 19.75% | — | — | — | — | — | |
| Elevance Health Inc. | 16.93% | — | — | — | — | — | |
| Intuitive Surgical Inc. | 14.32% | — | — | — | — | — | |
| Medtronic PLC | 7.01% | — | — | — | — | — | |
| UnitedHealth Group Inc. | 24.09% | — | — | — | — | — | |
| ROE, Sector | |||||||
| Health Care Equipment & Services | 17.28% | — | — | — | — | — | |
| ROE, Industry | |||||||
| Health Care | 25.44% | — | — | — | — | — | |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
1 2021 Calculation
ROE = 100 × Net income ÷ Shareholders’ equity
= 100 × 2,092 ÷ 23,677 = 8.84%
2 Click competitor name to see calculations.
An analysis of the profitability metrics from 2016 to 2021 reveals a period of significant volatility in Return on Equity (ROE), characterized by a sharp decline in the early years followed by a partial recovery. The ROE peaked at 12.79% in 2016 but experienced a substantial contraction, reaching a low of 1.48% in 2018, before rebounding to 8.84% by the end of the period.
- Net Income Fluctuations
- Net income exhibited considerable instability throughout the period. After a moderate increase in 2017, a severe contraction occurred in 2018, where earnings dropped to 311 million USD. While a recovery was observed in 2019 and 2021, with the latter marking a period high of 2,092 million USD, these fluctuations contributed directly to the inconsistency of the ROE.
- Shareholders' Equity Expansion
- A consistent and aggressive increase in shareholders' equity is observed from 2016 to 2020. The equity base grew from 7,633 million USD to 23,765 million USD. This expansion of the capital base exerted downward pressure on the ROE, as the growth in equity significantly outpaced the growth in net income for several consecutive years.
- ROE Correlation and Drivers
- The erosion of ROE between 2016 and 2018 was a result of the simultaneous occurrence of rising equity and plummeting net income. The recovery observed in 2021 to 8.84% was primarily driven by the surge in net income, as shareholders' equity remained relatively stagnant at 23,677 million USD, allowing the increased profitability to translate more effectively into a higher return for shareholders.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Return on Assets (ROA)
| Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||
| Net income | 2,092) | 874) | 1,233) | 311) | 1,100) | 976) | |
| Total assets | 53,866) | 54,012) | 51,765) | 53,904) | 37,734) | 25,586) | |
| Profitability Ratio | |||||||
| ROA1 | 3.88% | 1.62% | 2.38% | 0.58% | 2.92% | 3.81% | |
| Benchmarks | |||||||
| ROA, Competitors2 | |||||||
| Abbott Laboratories | 9.40% | — | — | — | — | — | |
| Elevance Health Inc. | 6.26% | — | — | — | — | — | |
| Intuitive Surgical Inc. | 12.58% | — | — | — | — | — | |
| Medtronic PLC | 3.87% | — | — | — | — | — | |
| UnitedHealth Group Inc. | 8.15% | — | — | — | — | — | |
| ROA, Sector | |||||||
| Health Care Equipment & Services | 7.28% | — | — | — | — | — | |
| ROA, Industry | |||||||
| Health Care | 9.46% | — | — | — | — | — | |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
1 2021 Calculation
ROA = 100 × Net income ÷ Total assets
= 100 × 2,092 ÷ 53,866 = 3.88%
2 Click competitor name to see calculations.
The period between 2016 and 2021 is characterized by significant volatility in net income and a substantial expansion of the asset base, which collectively drove fluctuations in the Return on Assets (ROA). While total assets increased sharply in the early part of the period, profitability exhibited a non-linear pattern, reaching a trough in 2018 before recovering to a period high by 2021.
- Asset Base Expansion
- Total assets experienced rapid growth between 2016 and 2018, increasing from US$ 25,586 million to US$ 53,904 million. Following this aggressive expansion, the asset base stabilized, remaining within a narrow range between US$ 51,765 million and US$ 54,012 million from 2019 through 2021.
- Net Income Trends
- Net income demonstrated considerable variance over the six-year span. A significant contraction occurred in 2018, with earnings dropping to US$ 311 million. This was followed by a recovery to US$ 1,233 million in 2019 and a subsequent decline to US$ 874 million in 2020. The period concluded with a sharp increase in profitability, reaching US$ 2,092 million in 2021.
- Return on Assets (ROA) Analysis
- The ROA reflects the combined impact of the expanding balance sheet and volatile earnings. The ratio declined from 3.81% in 2016 to a minimum of 0.58% in 2018, a decline driven by the simultaneous drop in net income and the peak in asset accumulation. A recovery trend followed, with the ROA climbing to 2.38% in 2019, dipping to 1.62% in 2020, and finally peaking at 3.88% in 2021. This final peak indicates that asset utilization efficiency returned to 2016 levels despite a significantly larger asset base.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?